Ethics in Psychiatry: Principles, Dilemmas, and Clinical Application

Why Psychiatric Ethics Is Distinct

Psychiatry occupies a peculiar space in medicine. Unlike cardiology or oncology, psychiatry retains the legal and moral authority to treat patients without their consent. Psychiatry has the power to administer medications that alter consciousness, insight, and personality. Psychiatry uniquely deals with patients whose illness impairs their very capacity to understand that they are ill. This asymmetry of power and knowledge creates ethical tensions not present in other medical fields.

The historical backdrop is crucial. The era of institutionalization (1850s–1970s) warehoused hundreds of thousands of patients in segregated asylums—often with minimal therapeutic benefit and pervasive neglect. The transorbital lobotomy era saw thousands of patients subjected to permanent neurological damage in the name of psychiatric treatment. The Tuskegee Syphilis Study (1932–1972) enrolled African American men with syphilis and deliberately withheld penicillin treatment to observe disease progression, exploiting psychiatric patients and racial minorities simultaneously. The Willowbrook hepatitis study deliberately infected mentally retarded children with hepatitis to test experimental vaccines. Soviet psychiatry weaponized diagnosis, confining political dissidents in psychiatric hospitals under the guise of "sluggish schizophrenia." These horrors forged modern psychiatric ethics—not as abstract philosophy but as hard-won protections against institutionalized harm.

Core Bioethical Principles in Psychiatry

Beauchamp and Childress identified four foundational principles in medical ethics. Each applies to psychiatry, yet each becomes complicated when filtered through psychiatric practice:

Autonomy: Respect for Patient Self-Determination

Autonomy is the principle that persons are ends in themselves, not mere means to ends. Patients possess the right to make decisions about their own bodies and medical care, even decisions that contradict medical advice. In psychiatry, autonomy is both paramount and fragile.

Informed consent is the mechanism by which autonomy is operationalized. Three elements are required: (1) capacity—the patient's cognitive and legal ability to understand and decide; (2) disclosure—the clinician provides information about the treatment, its risks, benefits, and alternatives; and (3) voluntariness—the patient chooses free from coercion or undue influence. Each element is contestable in psychiatry.

Capacity assessment relies on the four Appelbaum criteria [1]: understanding (can the patient comprehend information about the treatment?), appreciation (can the patient apply that information to their own situation?), reasoning (can the patient manipulate information logically?), and expressing a choice (can the patient communicate a decision?). Critically, capacity is decision-specific—a patient may have capacity to refuse medication but lack capacity to refuse hospitalization. It is also functional, not categorical: a patient with schizophrenia can possess the cognitive abilities needed for a particular decision.

The default legal presumption is that all patients possess capacity unless demonstrated otherwise. A patient's refusal to accept treatment is not, by itself, evidence of incapacity. A patient with psychosis who refuses antipsychotics may fully understand the information, appreciate their illness, and reason through the decision—they simply disagree with the clinician's recommendation. This is their right.

In scenarios where capacity is genuinely impaired—florid psychosis with delusions that prevent understanding, severe depression with suicidal intent, acute mania with poor judgment—the psychiatrist faces a choice: respect autonomy even as it is compromised, or invoke paternalism to protect the patient. This is the fundamental ethical tension.

Beneficence: Duty to Act in the Patient's Best Interest

Beneficence obligates the clinician to act in ways that benefit the patient. In psychiatry, this principle is complicated by the fact that what the clinician believes is beneficial may directly contradict what the patient wants.

The tension with autonomy is acute: what if a depressed patient refuses antidepressants that would almost certainly help? What if a patient in an acute manic episode refuses mood stabilizers? What if a patient with schizophrenia refuses an antipsychotic that previously controlled their symptoms? Beneficence might suggest override the patient's wishes and treat. Autonomy insists the patient's choice be honored.

One proposed resolution is the "thank you" theory of involuntary treatment: if a patient were restored to a state of capacity and wellness, would they look back and agree the involuntary treatment was justified? This is speculative and fraught with post-hoc rationalization, but it points toward a middle ground—paternalism is justified if it prevents irreversible harm and is consistent with the patient's own prior values.

In practice, beneficence requires careful documentation of the reasoning: Why is this treatment in the patient's best interest? What alternatives were considered? Has the patient's capacity been formally assessed? The difference between justified paternalism and coercive abuse often hinges on this documentation and clinical reasoning.

Non-Maleficence: First, Do No Harm

The principle of non-maleficence obligates clinicians to minimize harm. In psychiatry, "harm" is multifaceted: medication side effects, the psychological trauma of involuntary hospitalization, the stigma of psychiatric diagnosis, loss of autonomy, and the harm of withholding beneficial treatment.

Medication side effects are a primary source of harm. Antipsychotics cause metabolic syndrome, tardive dyskinesia, and extrapyramidal effects. Antidepressants cause weight gain, sexual dysfunction, and withdrawal syndromes. Benzodiazepines cause dependence and cognitive impairment. Lithium causes renal and thyroid complications. These harms are real and lasting. Ethical practice requires informed consent about side effects, monitoring for their emergence, and willingness to adjust treatment if harm outweighs benefit.

The harm of involuntary treatment is often underestimated. Patients experience forced hospitalization and medication as traumatic. It damages the therapeutic alliance and deters future help-seeking. Some patients develop lasting distrust of psychiatry after involuntary commitment. Non-maleficence requires using the least restrictive alternative—hospitalization only when necessary, medications only with clear indication, duration proportional to risk.

Labeling and stigma are also harms. A diagnosis of schizophrenia, borderline personality disorder, or bipolar disorder carries social stigma that may limit employment, relationships, and self-perception. The clinician must weigh diagnostic clarity against these social consequences.

Justice: Fair Distribution of Resources and Treatment

Justice in psychiatry encompasses two domains: distributive justice (fair allocation of psychiatric resources and treatment access) and procedural justice (fair processes when rights are restricted, as in involuntary commitment).

Disparities in psychiatric care are well-documented. Black and Hispanic patients receive less intensive treatment for depression and anxiety. Rural and underserved populations have minimal access to psychiatrists. Patients with lower education and income receive more medication and less psychotherapy. Forensic psychiatry creates a two-tiered system where incarcerated individuals receive minimal psychiatric care.

Justice demands that clinicians recognize these disparities and advocate for equitable resource allocation. This may mean referring patients to sliding-scale clinics, supporting parity legislation for mental health insurance, and working within systems to reduce racial and economic bias in treatment decisions.

Procedural justice requires that when autonomy is restricted—involuntary commitment, medication over objection, loss of visitor rights—the process be transparent, the patient have right to counsel and appeal, and clear standards guide the decision. Legal precedents like O'Connor v. Donaldson (1975) established that "liberty" cannot be deprived on the basis of "mental illness alone" but requires clear dangerousness or grave disability. Modern law requires periodic review of commitment and, in many jurisdictions, a judicial hearing before medication over objection can be imposed.

Informed Consent in Psychiatry

Informed consent is the lynchpin of ethical psychiatric practice. Yet psychiatry presents challenges to each of its three elements.

Capacity assessment is the first challenge. A patient with acute psychosis may not understand that they have schizophrenia—the delusions prevent insight. Severe depression may impair reasoning and future orientation, making it difficult for the patient to weigh risks and benefits. Mania may produce grandiosity that impairs appreciation of risk. The psychiatrist must formally assess each element of the Appelbaum criteria before proceeding with treatment.

In practice, capacity assessment is often informal and undocumented. The clinician observes the patient's conversational ability, apparent understanding, and willingness to engage. Formal capacity assessment tools (MacCAT-T, UCSD Brief Assessment of Capacity to Consent) may be used in contested cases or when capacity is genuinely uncertain. The bar for capacity should be proportional to the consequences: refusing low-risk medication requires lower capacity than refusal of ECT or surgery.

Disclosure of risks and benefits must be comprehensive. This includes: the diagnosis (if known), the proposed treatment and how it works, expected benefits based on research, common and serious side effects, alternatives (including no treatment), and consequences of refusal. For medications, specific discussion of dependence potential (benzodiazepines, opioids), sexual side effects (SSRIs), weight gain (antipsychotics), and long-term risks (tardive dyskinesia with antipsychotics, renal effects with lithium) is ethically required.

Documentation of disclosure is important for legal protection and clinical practice. Many practices use standardized consent forms for medications and treatments. However, a checkbox on a form is insufficient—the clinician should discuss these issues conversationally and assess the patient's understanding.

Voluntariness is the most insidious challenge. A patient in an emergency department following a suicide attempt faces implicit pressure to accept psychiatric hospitalization. A patient in an involuntary hold lacks genuine voluntariness in consenting to medication. A patient with a conservator or guardian experiences their autonomy as already compromised. In these scenarios, the consent is technically valid but ethically compromised. Good practice involves exploring the patient's values and preferences even when autonomy is legally constrained, and respecting values-based refusals when clinically feasible.

Special challenges include patients who lack insight (understanding their illness), patients under involuntary hold, and specific treatments like electroconvulsive therapy (ECT) and medication over objection. In most jurisdictions, patients retain the right to refuse medication even when involuntarily committed, unless emergency dangerousness justifies forced medication. Medication over objection requires a separate judicial hearing (Rennie v. Klein, Rogers v. Commissioner) in which the patient's interest in bodily integrity is weighed against state interest in treatment. ECT requires explicit, documented consent and, in some jurisdictions, judicial approval.

Confidentiality and Its Limits

The therapeutic alliance is built on confidentiality. Patients disclose violence fantasies, suicidal ideation, shameful secrets, and traumatic memories only if they trust the clinician will maintain confidentiality. Breach of confidence destroys the alliance and deters future help-seeking.

Absolute confidentiality does not exist in psychiatry or medicine. The law recognizes mandatory exceptions where public safety or the patient's safety overrides confidentiality.

Duty to warn and protect originated in Tarasoff v. Regents of the University of California (1976). A university counselor was sued after failing to warn a woman that her patient had stated intention to kill her. The court ruled that when a patient poses a serious threat of violence to an identifiable person, the therapist has a duty to warn that person or otherwise protect them. Most states have adopted Tarasoff obligations. The standard typically requires: (1) a serious threat of violence, (2) an identifiable victim, (3) reasonable foreseeability that the threat will be carried out. Mere fantasy or expression of rage does not trigger the duty. A patient saying "I've thought about killing my boss" during therapy is not the same as a patient saying "I plan to kill my boss when I leave work today."

In practice, when a patient expresses suicidal or homicidal intent, the clinician should: assess the immediacy and lethality of the threat, develop a safety plan (hospitalization if necessary), document thoroughly, and consult with colleagues. If a specific identifiable person is at imminent risk, warning that person or law enforcement may be necessary and is legally protected.

Mandatory reporting of abuse is another exception to confidentiality. All states require reporting of child abuse and neglect. Most require reporting of elder abuse and dependent adult abuse. These reporting obligations exist independent of the patient's wishes and supersede confidentiality. A clinician cannot maintain confidentiality if a patient discloses they are abusing a child or that an elderly parent is being neglected.

HIPAA considerations govern medical information sharing. The Privacy Rule allows disclosures for treatment, payment, and operations without explicit consent. Disclosures to family members require balancing confidentiality with the clinical need to involve family in treatment. Routine practice is to contact family members for collateral history when the patient consents; when the patient is incompetent or uncooperative, limited disclosure (confirming the patient is under care, discussing general treatment approach) may be appropriate.

Gray areas abound. Can you discuss a patient's case with a consulting neurologist without explicit consent? (Yes, if it's for treatment.) Can you contact a patient's family to discuss medication side effects if the patient refuses? (Generally no, unless imminent safety risk.) Can you disclose information to a patient's employer about a medical leave? (Only with explicit consent.) The principle is "minimum necessary"—disclose only what is essential for the immediate clinical or legal purpose.

Boundary Ethics and the Therapeutic Relationship

Professional boundaries in psychiatry are stricter than in most medical specialties because the psychiatric relationship is inherently unequal. The therapist holds power through their knowledge, the patient's vulnerability, and the phenomenon of transference—the patient's projection of past relational patterns onto the clinician.

Boundary crossings are minor deviations from standard practice that may not be harmful. Accepting a small handmade gift from a patient, briefly touching a patient's shoulder in compassion, or sharing a relevant personal anecdote—these are crossings. They depart from strict neutrality but may serve the therapeutic relationship.

Boundary violations are serious breaches that exploit the patient or depart from the standard of care. Sexual contact with a patient is never acceptable—not once, not after therapy ends, not with a "consenting adult." The power imbalance makes true consent impossible. Sexual violation is the most serious ethical breach in psychiatry and typically results in license revocation, criminal charges, and civil liability [2].

Financial exploitation—loaning money to patients, accepting business deals, involving the patient in the clinician's financial schemes—is also a clear violation. Dual relationships (being both therapist and friend, employer, or social acquaintance) create conflicts of interest and impair clinical judgment.

Self-disclosure by the clinician can be therapeutic when brief, relevant, and for the patient's benefit. Sharing that you also struggle with anxiety may normalize the patient's experience. Disclosing that a family member had schizophrenia may reduce shame. However, excessive self-disclosure—burdening the patient with your own problems, making the patient your emotional support—shifts the dynamic and becomes exploitative.

Social media and digital boundaries present new ethical challenges. Friending patients on Facebook, viewing their Instagram, or messaging outside appointment hours blurs professional and personal boundaries. Most guidelines recommend avoiding social media contact with current patients. Even after therapy ends, friending a former patient 2 years later may blur boundaries that should remain clear.

The principle underlying boundary ethics is simple: the relationship exists for the patient's benefit, not the clinician's. Anything that serves the clinician's emotional needs at the patient's expense is a violation.

The Ethics of Involuntary Treatment

Involuntary commitment and forced medication are psychiatry's most ethically fraught interventions. They represent a fundamental override of individual liberty in the name of protection or treatment. Understanding their ethical justification and limits is essential for ethical practice.

Legal justification rests on two doctrines. Parens patriae is the state's power to act as a protective parent for those unable to care for themselves. Police power is the state's authority to protect the public from harm. Involuntary commitment traditionally balanced both: the state could commit a person both for their own protection (parens patriae) and for public safety (police power).

The legal standard shifted dramatically with O'Connor v. Donaldson (1975). The Supreme Court ruled that "a state cannot constitutionally confine without more a non-dangerous individual who is capable of surviving safely in the community with the help of willing and responsible family members or friends." This decision shifted the focus from "need for treatment" or "mental illness" alone to dangerousness as the primary criterion for commitment. Modern civil commitment standards typically require: (1) mental illness, (2) danger to self or others, or (3) grave disability (inability to provide food, shelter, or medical care). Different states weight these criteria differently.

The harm of involuntary treatment is substantial and often minimized in clinical thinking. Patients experience involuntary hospitalization as traumatic, even when psychiatrists view it as lifesaving. The loss of autonomy, the locked unit, the forced medication—these are experienced as assaults on the self, not benevolent interventions. Some patients develop lasting distrust of psychiatry and clinicians after involuntary treatment, delaying help-seeking during future crises.

Research shows that shared decision-making and motivational interviewing reduce the need for involuntary commitment. A patient presented with empathy, given information about treatment options, and involved in the decision is more likely to accept voluntary hospitalization than a patient who is confronted, dismissed, or ordered. The ethical psychiatrist offers voluntary commitment first, explaining the rationale and offering alternatives (partial hospitalization, intensive outpatient care). Involuntary commitment is the last resort, not the first option.

Medication over objection requires heightened protection. In most jurisdictions, a patient who is involuntarily committed retains the right to refuse medication unless the medication is necessary to prevent imminent harm. Giving antipsychotics to a patient in restraints against their will for convenience (making them quieter, more manageable) is unethical and illegal. Giving antipsychotics to a patient experiencing command hallucinations urging violence is ethically justified as emergency intervention. The distinction hinges on immediacy of danger and lack of less restrictive alternatives.

Outpatient commitment (OAC, sometimes called "Kendra's Law" after Kendra Webdale, killed by a patient on AOT) mandates psychiatric treatment as a condition of avoiding hospitalization. The evidence is mixed: OAC reduces hospitalizations in some studies but raises serious autonomy concerns. Is forcing a patient to attend clinic and take medication in the community more ethical than allowing crisis hospitalization? The answer depends on one's weighting of autonomy versus beneficence. Ethically, OAC should involve: clear criteria (risk of hospitalization without it), shared decision-making when possible, regular review, and the option for patients to appeal the order.

Dual Agency and Forensic Ethics

Forensic psychiatry—the intersection of psychiatry and the legal system—creates a fundamental ethical conflict: the psychiatrist may be asked to serve as both healer and evaluator, both the patient's advocate and the court's expert. This dual agency is ethically problematic and often unresolvable.

The treating psychiatrist vs. the forensic evaluator have fundamentally different relationships and obligations. A treating psychiatrist's duty is to the patient: confidentiality, beneficence, advocacy. A forensic evaluator's duty is to the court: objective assessment, candor about limitations, no therapeutic promise. The Strasburger warning (named to landmark paper by clinicians Paul Strasburger) is that clinical and forensic roles are fundamentally incompatible. A psychiatrist cannot be both the patient's therapist and a forensic evaluator for the same person.

Common forensic contexts include: fitness for duty evaluations (is an employee fit to work?), independent medical examinations (IMEs) for disability or workers' compensation, criminal responsibility evaluations (did the defendant's mental illness prevent them from appreciating the criminality of their act?), competency to stand trial evaluations (can the defendant understand the charges and assist in their defense?), and commitment evaluations (does the person meet criteria for involuntary hospitalization?). In each, the psychiatrist must clarify at the outset: "I am not your treating physician. I am evaluating you for the court. What I find will be reported to the court, not to you. You are not my patient."

Confidentiality in forensic work is limited. The forensic patient should understand that statements made are not confidential and will be disclosed to the referring attorney or court. Documentation should be objective, thorough, and acknowledge uncertainties and alternative explanations. Bias—either toward the referring party (prosecution, defense, plaintiff, or employer) or against the client—undermines forensic work.

The Goldwater Rule (American Psychiatric Association Principle 7.3) states: "A psychiatrist should not offer a professional opinion unless he or she has conducted an examination and has been granted permission for such use" [3]. The rule was established after psychiatrists offered opinions about Barry Goldwater's mental fitness for the presidency in 1964 (the FACT magazine survey). The concern was that remote diagnosis, without examination, is speculative and potentially harmful. Modern application: psychiatrists should not opine on the mental health of public figures, politicians, or celebrities without examination. This rule applies even in the social media era, where armchair diagnosis is common.

Ethics of Prescribing

Psychiatric prescribing ethics involve navigating off-label use, controlled substances, pharmaceutical influence, and polypharmacy.

Off-label prescribing (using an FDA-approved drug for an indication not approved) is ubiquitous in psychiatry. Quetiapine for insomnia, gabapentin for anxiety, propranolol for akathisia—these are standard practice but not FDA-approved for these indications. Off-label prescribing is legally permissible but ethically requires informed consent. The patient should understand: "This medication is approved by the FDA for [indication], but many clinicians use it for [indication] based on clinical experience and research. The evidence is [strong/moderate/limited]." Documentation of this discussion is important.

Controlled substances and benzodiazepines present ethical challenges. Benzodiazepines are highly effective for acute anxiety but carry risk of dependence and abuse. Ethical prescribing requires: clear indication (acute anxiety, not chronic anxiety), short-term use (weeks to months, not years), regular reassessment, monitoring for dependence behaviors, and documentation of risk-benefit analysis. The opioid crisis is a cautionary tale about how enthusiasm for medication (in that case, opioids) combined with pharmaceutical marketing, prescriber bias, and inadequate monitoring of dependence risk created a public health catastrophe [4].

Pharmaceutical industry influence is pervasive. Gifts (meals, pens, notepads), speaking honoraria, continuing education funding, and free samples create subtle bias. Research shows that gifts, even small ones, influence prescribing toward promoted drugs. The Physician Payments Sunshine Act (part of the Affordable Care Act) requires transparency: all payments to physicians by pharmaceutical companies are publicly reported. Ethical practice requires awareness of this influence and deliberate effort to base prescribing on evidence rather than marketing.

Polypharmacy (prescribing multiple medications) is common in psychiatry and often necessary (e.g., antipsychotic + mood stabilizer + anxiolytic + sleep aid). However, polypharmacy can also reflect diagnostic uncertainty, pressure from patients for symptom relief, or inertia (simply continuing medications started years ago). Good practice involves periodic review: Are all medications necessary? Are drug-drug interactions managed? Has the regimen drifted from evidence-based practice? Deprescribing (carefully tapering unnecessary medications) is an underutilized ethical practice.

Ethics at the End of Life

Psychiatric ethics extend to end-of-life decisions, where psychiatric illness, autonomy, and death intersect.

Physician-assisted death (PAD) or medical aid in dying (MAID) is legal in some jurisdictions. Jurisdictions that permit PAD typically exclude patients whose sole qualifying condition is psychiatric. The reasoning is that psychiatric illness impairs judgment and suicidality is a symptom, not a rational end-of-life decision. However, in the Netherlands and Belgium, MAID has been extended to patients with treatment-resistant psychiatric illness (severe depression, anorexia) when suffering is severe and refractory. This remains controversial. The ethics center on: (1) whether psychiatric illness can ever be "terminal" or "irremediable," (2) whether the patient's preference for death reflects their authentic values or the illness, and (3) society's obligation to continue offering treatment versus respecting autonomy.

Advance directives in psychiatry are underutilized but valuable. A psychiatric advance directive (PAD) allows patients to specify treatment preferences during periods of capacity for use if they lose capacity during a crisis. For example, a patient with bipolar disorder might document: "In a manic episode, I want to go to Hospital X, not Hospital Y. I accept antipsychotics but not lithium due to side effects. Do not put me in restraints unless absolutely necessary. Call my sister, not my mother, for collateral information." These directives respect autonomy and reduce the need for coercive interventions by honoring the patient's prior values.

Withholding treatment in severe eating disorders raises profound ethical questions. A patient with anorexia nervosa may refuse refeeding even knowing it will lead to death. Does respecting autonomy mean allowing the patient to die? The distinction between refusal of life-sustaining treatment (ethically and legally permitted) and active suicide is philosophically unclear. Good practice involves: assessing capacity to make end-of-life decisions, exploring values and fears about refeeding, offering less-restrictive alternatives (outpatient treatment, slower refeeding), and involving ethics consultants in difficult cases.

Ethical Decision-Making Frameworks

When ethical principles conflict, the four-box method (developed by Jonsen, Siegler, and Winslade) provides structure [5]:

Box 1: Medical Indications. What is the medical problem? What are the treatment options and their likely outcomes? Is the prognosis clear? This is the empirical foundation.

Box 2: Patient Preferences. What are the patient's values, goals, and wishes? Has the patient expressed prior preferences (advance directives, conversations with family)? Is the patient able to participate in decision-making? If not, what would the patient want if they could decide?

Box 3: Quality of Life. How will the illness and treatment affect the patient's well-being? What does the patient value in life? What are the patient's fears and concerns?

Box 4: Contextual Features. Are there family or social issues that bear on the decision? Are there resource limitations? Are there relevant legal or religious considerations?

Working through each box clarifies the values and facts at stake. Often, the ethical path becomes clearer when the relevant considerations are explicitly stated.

Ethics consultation is available at most hospitals. An ethics committee or consultant can help navigate difficult cases, ensure all perspectives are heard, and provide guidance on ethically sound decisions. Requesting ethics consultation is not a sign of weakness but of respect for the complexity of ethical practice.

Documentation is ethically and legally important. When ethical dilemmas arise, document: the clinical situation, the alternatives considered, the patient's preferences and capacity, the reasoning for the decision, and consultations obtained. Good documentation demonstrates ethical deliberation and protects both patient and clinician.

Key Takeaways for Clinicians

Psychiatric ethics is not abstract philosophy. It is rooted in the lived experience of patients, the power imbalances inherent in psychiatric treatment, and hard-won legal protections forged after historical abuses. A few core principles guide ethical practice:

Presume capacity until demonstrated otherwise, and remember that capacity is decision-specific, not global. A refusal of treatment is not evidence of incapacity.

Respect autonomy even when it conflicts with your clinical judgment. Informed consent is not a checkbox; it is an ongoing conversation about the patient's values and preferences.

Minimize harm by using the least restrictive alternative, monitoring for medication side effects, and recognizing that involuntary treatment itself causes harm.

Maintain boundaries with clarity about the therapeutic relationship's purpose: it exists for the patient's benefit, not the clinician's.

Disclose conflicts of interest, including pharmaceutical relationships, financial arrangements, and dual roles (clinician and evaluator). Transparency is foundational to trust.

Document ethical reasoning when dilemmas arise. The documentation protects both patient and clinician and demonstrates good faith engagement with complexity.

Consult colleagues or ethics committees when uncertain. Ethical practice is not a solitary endeavor; it benefits from multiple perspectives and collective wisdom.

The ethical psychiatrist recognizes that power asymmetry is built into the relationship. This asymmetry can be misused—to coerce, exploit, or harm. Or it can be used ethically—to protect vulnerable patients, to treat illness with evidence-based care, to respect autonomy even when it is imperfect. The difference lies in ethical awareness, ongoing self-reflection, and commitment to the patient's welfare above the clinician's convenience or preference.